ARTICLE | Clinical News
Crisaborole: Phase III data
July 20, 2015 7:00 AM UTC
Top-line data from the double-blind, U.S. Phase III AD-302 trial in 763 patients ages >=2 with mild to moderate atopic dermatitis showed that twice-daily topical 2% crisaborole for 28 days met the pri...